• ArkAb introduction

  • ArkAb's offer for in vitro diagnostics industry and research in immunology

  • ArkAb - B Cell Design team

  • ArkAb human chimeric monoclonal Antibodies (huchimAbs) products

  • ArkAb process to obtain human chimeric monoclonal antibodies (mAbs) : purification picture

  • ArkAb human chimeric monoclonal Antibodies (mAbs) development

  • ArkAb human chimeric monoclonal Antibodies (mAbs) cell culture

ArkAb new products anti-SARS-COV-2

ArkAb developed raw materials for the quality controls of immunoassays looking for Ig anti-SARS-COV-2 in patients samples. These products will be available for IVD manufacturers first quarter of 2021.

Read more

ArkAb new work organization

During the pandemic, ArkAb and B Cell Design had to protect their teams first so adapt working conditions: working organization, answer to containment measures...

Read more

ArkAb catalog online

ArkAb catalog is now available online!

Read more

ArkAb, the Antibody Solution

ArkAb is a deep tech company pioneer in the field of synthetic antibodies as an alternative to human disease state plasma for in vitro diagnostic industry.

ArkAb is a spin-off of an internal department of B cell Design established in 2016 in Limoges, France. But ArkAb activity started in 2009 under its parent company through its partnership with bioMérieux for which several projects have been developed.

ArkAb develops, manufactures and commercialize innovative raw materials for in vitro diagnostic market and for research in immunology.

ArkAb was founded in 2018 with the vision to make robust engineered chimeric antibodies accessible to manufacturer of diagnostic kits and research laboratories. ArkAb's offer remains the only one focused on innovative antibody technologies for the development and manufacturing of human chimeric monoclonal IgM, IgG, IgA and IgE to provide solutions for a large panel of indications: infectious diseases, autoimmunity, inflammatory disorders, physiologic disorders, allergies and food intolerances.

Since 2016 ArkAb's vision is that though synthetic antibodies are standard in the pharmaceutical industry, these antibodies have not been as widely available for diagnostics or research. ArkAb's expertise, technologies and know-how allow today a mutation of this market thanks a reliable solution of generation of antibodies with a very high added value. Arkab offers its synthetic products as raw materials for the positive controls, quality controls and calibrators of immunoassays. This offer remains complementary to that of recombinant antibodies by providing a breakthrough approach, making it possible to monitor efficiently the development of antibodies with human features for complex specifications on sensitive and complicated indications.

ArkAb presentation video ArkAb presents its activity through a movie in English: https://youtu.be/6i_X80HZF4E and in Chinese: https://youtu.be/shNa7DWOksk


ArkAb products are human chimeric monoclonal antibodies (human constant region of the heavy chain) for research or further manufacturing use. They are used:

- as raw materials for immunoassay quality controls for a reliable, secure and reproducible alternative to disease state plasma

- as immunocapture antibodies to avoid HAMA issues (human antibody directed against mouse antibody)

- the same way as other monoclonal antibodies. Thanks to patented technologies, ArkAb is able to develop human chimeric mAbs with complex features (functionality and reactivity, specific antigen, wished human isotype etc...)

ArkAb offers catalog products and custom made development services with flexible and adaptable business models.

ArkAb already developed human chimeric antibodies directed against a wide range of antigens: recombinant proteins, peptides, DNA, hapten, allergens etc...

After immunization and polyclonal answer monitoring, ArkAb does fusions of the splenocytes with myeloma cell line to obtain hybridomas. Hybridomas are screened for reactivity against the antigen. Then cross reactivity is checked and cell lines are prepared for antibody industrial bioproduction.


This website uses cookies, by continuing to browse this website you agree to our cookie policy.